We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

Back to rankings

1 hedge funds and large institutions have $52K invested in SALIX PHARMACEUTICALS LTD DEL in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 297 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 298 → 1 (-297)

100% less funds holding in top 10

Funds holding in top 10: 47 → 0 (-47)

100% less capital invested

Capital invested by funds: $10.8B → $52K (-$10.8B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 297

Holders
1
Holders Change
-297
Holders Change %
-99.66%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-47
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
297
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
-$950M
2
PCM
Pentwater Capital Management
Florida
-$652M
3
State Street
State Street
Massachusetts
-$376M
4
YCMGA
York Capital Management Global Advisors
New York
-$327M
5
BIT
BlackRock Institutional Trust
California
-$317M
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
226
LPL Financial
California
– -$861K -4,977 Closed
Royal Bank of Canada
227
Royal Bank of Canada
Ontario, Canada
– -$834K -4,825 Closed
GF
228
Gerstein Fisher
New York
– -$799K -4,624 Closed
SMDAM
229
Sumitomo Mitsui DS Asset Management
Japan
– -$789K -4,571 Closed
SC
230
Saturna Capital
Washington
– -$780K -4,512 Closed
CPA
231
Cowen Prime Advisors
New York
– -$778K -4,500 Closed
WSTAM
232
Wilbanks Smith & Thomas Asset Management
Virginia
– -$639K -3,700 Closed
Janus Henderson Group
233
Janus Henderson Group
United Kingdom
– -$633K -3,665 Closed
Bank of Montreal
234
Bank of Montreal
Ontario, Canada
– -$609K -3,524 Closed
M&T Bank
235
M&T Bank
New York
– -$573K -3,316 Closed
BCIM
236
British Columbia Investment Management
British Columbia, Canada
– -$569K -3,290 Closed
EGM
237
Engineers Gate Manager
New York
– -$550K -3,185 Closed
DBG
238
De Burlo Group
Massachusetts
– -$535K -3,100 Closed
SKK
239
Shepherd Kaplan Krochuk
Massachusetts
– -$527K -3,049 Closed
OI
240
Oakbrook Investments
Illinois
– -$510K -2,950 Closed
HHMI
241
Howard Hughes Medical Institute
Maryland
– -$500K -2,894 Closed
CIM
242
Calvert Investment Management
Maryland
– -$491K -2,843 Closed
DL
243
Delta Lloyd
Netherlands
– -$480K -2,777 Closed
VKH
244
Virtu KCG Holdings
New York
– -$475K -2,750 Closed
TD Asset Management
245
TD Asset Management
Ontario, Canada
– -$448K -2,592 Closed
Truist Financial
246
Truist Financial
North Carolina
– -$388K -2,246 Closed
KTC
247
Kistler-Tiffany Companies
Pennsylvania
– -$380K -2,200 Closed
William Blair & Company
248
William Blair & Company
Illinois
– -$379K -2,194 Closed
US Bancorp
249
US Bancorp
Minnesota
– -$360K -2,081 Closed
ES
250
Equitec Specialists
Illinois
– -$347K -2,009 Closed
8 9
10
11 12

SLXP Hedge Fund Activity: Q2 2015 in Review

1 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q2 2015, worth a combined $52K — down 100% from $10.8B a quarter earlier.

Sellers outnumbered buyers: 297 funds closed out of SLXP and 0 opened new positions — a net loss of 297 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Paulson & Co, exiting entirely with an estimated $950M sold.

  • 1 institutional investor held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q2 2015, down from 298 in Q1 2015.
  • Funds reported $52K of SALIX PHARMACEUTICALS LTD DEL stock for Q2 2015, down 100% quarter-over-quarter.
  • 0 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q2 2015 and 297 closed out, a net change of -297 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q2 2015 was Paulson & Co, an estimated $950M sold.

Based on aggregated 13F filings for Q2 2015.